Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors

US10138248B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Andrew W. Buesking · Wilmington, US
• Richard B. Sparks · Linwood, US
• Andrew P. Combs · Kennett Square, US
• Brent Douty · Coatesville, US
• Nikoo Falahatpisheh · Wilmington, US
• Lixin Shao · Wilmington, US
• Stacey Shepard · Wilmington, US
• Eddy W. Yue · Landenberg, US

Key dates

• Filing date: Jun 23, 2017
• Grant date: Nov 27, 2018
• Expiry date: Jun 23, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.